PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a
clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais,
M.D., Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2nd Annual Healthcare Conference being held
at the Sofitel New York in New York, New York on September 27, 2016. Ocera’s presentation will take place in the Track 4 Orleans
Room at 12:00 PM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the
conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of
OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted
orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia
and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional
information, please see www.ocerainc.com.
OCRX-G
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
contact@ocerainc.com
919-328-1109